GeneDx Holdings Corp. (WGS)

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.   NEW YORK, Feb. 25, 2026 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of GeneDx Holdings Corp. (NASDAQ: WGS) breached their fiduciary duties to shareholders.

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) announced that company management will participate in the upcoming TD Cowen and Barclays healthcare investor conferences.

GeneDx Holdings Corp (NASDAQ: WGS) reported better-than-expected fourth-quarter financial results on Monday.

GeneDx (WGS) is upgraded to 'Buy' as valuation resets and operational improvements support a more realistic growth outlook. Per my DCF model, WGS now targets 25% CAGR and 10% free cash flow margins, with potential to reach 14% FCF margin, making its valuation less stretched. Management plans to nearly triple its commercial footprint in 2026, prioritizing growth capture over near-term margins and signaling a ramp toward 2027 acceleration.

GeneDx Holdings Corp. (WGS) Q4 2025 Earnings Call Transcript

GeneDx Holdings Corp. (WGS) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.7 per share a year ago.

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS) today reported its financial results for the fourth quarter and full year of 2025.

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS) today reported its financial results for the fourth quarter and full year of 2025.

GAITHERSBURG, Md.--(BUSINESS WIRE)--TIME Names GeneDx CEO Katherine Stueland to the 2026 TIME100 Health List.

DUBAI, Feb. 9, 2026 /PRNewswire/ -- CanSino Biologics Inc. ("CanSinoBIO"; SSE: 688185, HKEX: 06185) has been invited to share the practices of innovative vaccine at the World Government Summit 2026 (WGS 2026) which convened from February 3 to 5 in Dubai, UAE under the theme of "Shaping Future Governments." CanSinoBIO stands the sole global vaccine maker invited to the World Government Summit for the second consecutive year.

The Portfolio returned -1.3% gross and -1.5% net compared to the 1.2% return of the Russell 2000 Growth Index. Bloom Energy announced better than expected results with added optimism from a $5B partnership with Brookfield as the preferred onsite power provider. GeneDx delivered better-than-expected results—including raised full-year guidance—driven by a significant year-over-year increase in high value testing volumes.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of GeneDx Holdings Corp. (NASDAQ: WGS) breached their fiduciary duties to shareholders. If you currently own GeneDx stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved financial incentive award, or other relief and benefits. Please click here to learn more about your le.

GeneDx Holdings Corp. (WGS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

GeneDx Holdings Corp. is positioned as a leader in advanced exome and genome diagnostics, leveraging its expanding rare disease dataset. Fourth quarter preliminary results met guidance but did not exceed it sufficiently for a high multiple stock, resulting in a pullback. Company's 2026 guidance was strong and above expectations with testing volume growth of 33-35%.

GeneDx stock (NASDAQ: WGS) plunged 14% on Monday after the genomics testing company released preliminary full-year 2025 results that met expectations. But the company unveiled 2026 guidance that investors deemed disappointingly conservative, wiping out significant gains and reigniting concerns about the high-growth biotech's ability to maintain breakneck expansion.

WGS collaborates with Komodo Health to link genomic data with real-world insights, expanding data monetization and strengthening its role in rare disease research.